“The existing situation has exposed some structural weaknesses during the EU’s medicines supply chain along with a substantial dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides stated. She proposed that offer chain challenges be dealt with within an EU pharmaceutical tactic expected being introduc